Is Bimzelx Approved for Psoriasis and Psoriatic Arthritis?
Yes, Bimzelx (bimekizumab-bkzx) is FDA-approved for both moderate-to-severe plaque psoriasis in adults and active psoriatic arthritis in adults.[1][2]
When Did Approvals Happen?
The FDA approved Bimzelx for plaque psoriasis in October 2023, based on Phase 3 trials showing skin clearance in 85-91% of patients at week 16.[1] Approval for psoriatic arthritis followed in June 2024, supported by BE OPTIMAL and BE COMPLETE studies where 45-62% achieved joint improvement (ACR50) at week 16.[2]
How Does Bimzelx Work for These Conditions?
Bimzelx targets IL-17A and IL-17F cytokines, which drive inflammation in psoriasis skin plaques and psoriatic arthritis joint damage. This dual blockade differentiates it from single-IL-17 inhibitors like Cosentyx (secukinumab).[3]
Who Makes Bimzelx and What's the Dosing?
UCB manufactures Bimzelx. Dosing is 320 mg (two 160 mg injections) every 4 weeks for psoriasis; for psoriatic arthritis, it's the same after initial loading, with or without methotrexate.[1][2]
What About Patents and Biosimilars?
Bimzelx's key U.S. patents expire in the 2030s, per DrugPatentWatch.com—check DrugPatentWatch.com for exact dates and challenges.[4] No biosimilars are approved yet.
Common Side Effects Patients Report
Upper respiratory infections (15-20%), oral candidiasis (7-14%), and injection site reactions occur most often. Serious risks include infections and hypersensitivity.[1][2]
How Does It Compare to Other IL-17 Inhibitors?
| Drug | Targets | PsO Approval | PsA Approval | Key Trial ACR50 (PsA, wk 16) |
|------|---------|--------------|--------------|------------------------------|
| Bimzelx | IL-17A/F | 2023 | 2024 | 45-62% |
| Cosentyx | IL-17A | 2015 | 2016 | 40-50% |
| Taltz | IL-17A | 2016 | 2019 | 35-45% |
Bimzelx shows higher skin clearance rates in head-to-head psoriasis data vs. adalimumab.[3]
Sources:
[1] FDA Label: Bimzelx (PsO) - fda.gov
[2] FDA Label: Bimzelx (PsA) - fda.gov
[3] NEJM: Bimekizumab vs Adalimumab (2020) - nejm.org
[4] DrugPatentWatch: Bimzelx Patents - drugpatentwatch.com